Mechanisms of Behavioral Activation (BA)
Emory University · with National Institute of Mental Health (NIMH) · NCT05548244
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 15–17 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 136
- US sites recruiting
- 3
- Study start
- January 30, 2023
- Record last updated
- June 1, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The investigators will be comparing brain (neural) activation of depressed adolescent patients before, during and after a course of Behavioral Activation (BA) therapy using functional magnetic resonance imaging (fMRI). In particular, the project seeks to determine whether BA targets different neural mechanisms for behavioral avoidance associated with low motivation as compared to threat avoidance. A group of healthy controls will also be scanned as a comparator group for behavioral and imaging measures.
Being studied: Behavioral Activation Therapy; Baseline assessment procedures
Conditions: Depression
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Male and female adolescents ages 15-17;
- current MDD diagnosis as determined by K-SADS-PL,
- CDRS-R raw score > 45 (T-score > 65) at baseline;
- estimated full scale IQ > 80 as determined by the WASI-II;
- able to receive outpatient care;
- willing to not partake in other psychosocial treatments;
- not taking psychotropic medications in the two weeks (four weeks for fluoxetine) prior to consent, with the exception of psychostimulant medication prescribed for the treatment of ADHD.
- Additionally, depressed patients must have access to required technology (e.g. smart phone, tablet, or desktop computer) to complete the EMA portion of the study.
- Healthy controls cannot not meet criteria for MDD and their CDRS-R raw score must be below 28; T-score \< 52).
Exclusion Criteria
- Current or past diagnosis of bipolar, schizophrenia, schizophreniform, schizoaffective disorders, or psychosis NOS;
- current diagnosis of developmental disorder, severe conduct disorder, life-threatening anorexia, OCD, or autism-spectrum disorders;
- taking psychotropic medications prior to entry;
- estimated IQ \< 80; alcohol/drug dependence or abuse within the last 3 months;
- potential/confirmed neurological disorder or epilepsy;
- claustrophobia;
- presence of a medical condition that precludes fMRI;
- endorsement of imminent and serious suicidality;
- medical conditions that take precedence over the presence of MDD;
- pregnancy;
- substance use (excluding nicotine) within two weeks of the fMRI scan;
- left-handedness;
- nicotine use within 3 hours of the fMRI scan;
- history of traumatic brain injury or of being unconscious for more than 30 minutes;
- a stimulant regime for ADHD which has changed within 30 days of the fMRI scan.
- Non-compliance (i.e. \<70% completion) or inability (i.e. lack of smartphone device) to complete the 3 assessment periods of EMA.
Recruiting US locations
Emory University
Atlanta, GA 30322
Site contact: Wade E Craighead, PhD · ecraigh@emory.edu
Facility for Education and Research in Neuroscience (FERN)
Atlanta, GA 30322
Site contact: Michael Treadway, PhD · mtreadway@emory.edu
Child and Adolescent Mood Program (CAMP)
Atlanta, GA 30329
Site contact: Wade E Craighead, PhD · ecraigh@Emory.edu
Study contacts (from the official record)
- Wade E Craighead, PhD · 4047273287 · ecraigh@emory.edu
- Michael Treadway, PhD · mtreadway@emory.edu
Similar studies in Georgia
All mental health studies in Georgia →- RecruitingPhase 1Overnight stay mentioned
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
Leal Therapeutics, Inc
- Location
- Decatur, GA + 9 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 1Overnight stay mentioned
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
BioXcel Therapeutics Inc
- Location
- Decatur, GA + 3 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingHealthy volunteersEarly Phase 1
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Emory University
- Location
- Atlanta, GA
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteers
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
Ecotera Health LLC
- Location
- Atlanta, GA + 50 other US sites
- Eligibility basics
- Ages 18+